Orforglipron Age Requirements: Is It Safe for Teens or Older Adults?

Orforglipron age requirements are straightforward at one end and more nuanced at the other: the FDA label states that safety and effectiveness haven’t been established in pediatric patients, so there’s no approved use for anyone under 18. On the older end, clinical trials included a meaningful number of adults 65 and older, and the label reports no overall differences in safety or effectiveness compared with younger adults. Here’s what the label actually says about both groups, and why age is only one factor in a prescribing decision.

Is there a minimum age for orforglipron?

Yes. Orforglipron’s FDA-approved indication is chronic weight management in adults with obesity, or adults who are overweight with at least one weight-related condition, used alongside diet and physical activity. Per the FOUNDAYO label on DailyMed, the trials that supported approval (ATTAIN-1 and ATTAIN-2) enrolled adult participants, and the label explicitly states that safety and effectiveness of orforglipron have not been established in pediatric patients.

That single sentence carries real weight in FDA labeling: it doesn’t mean the drug has been tested in minors and found unsafe — it means it hasn’t been studied in that population at all for this indication, so there’s no approved basis for prescribing it to anyone under 18. For the full picture of who the drug is approved for, see Who Should Take Orforglipron?.

What the label says about older adults

Orforglipron isn’t age-restricted at the upper end the way it is at the lower end. Per the label, in a pool of the ATTAIN-1 and ATTAIN-2 trials:

Age group	Share of FOUNDAYO-treated trial patients
65 years or older	13% (399 patients)
75 years or older	1% (33 patients)

The label states that no overall differences in safety or effectiveness were observed between patients 65 and older and younger adult patients. That’s a reassuring data point, but it’s a population-level finding from a clinical trial, not an individual guarantee — the 75-and-older group in particular was small (just 33 patients), which is worth keeping in mind if you’re evaluating the drug for someone in that older age bracket.

Why “no overall differences” isn’t the same as “safe for everyone over 65”

A statement like this in an FDA label describes what researchers observed across a study population — it doesn’t replace an individual health evaluation. Older adults are more likely, on average, to have other conditions (reduced kidney function, multiple medications, other chronic illnesses) that a prescriber weighs independently of the age-related trial statistics. If GI side effects like nausea or vomiting lead to reduced fluid intake, that’s a general consideration prescribers pay closer attention to in older patients — see our orforglipron side effects guide for what to expect and watch for during titration.

Age also comes up indirectly through insurance: Medicare Part D primarily covers adults 65 and older, and coverage rules for weight-management GLP-1s have been evolving. If cost or coverage is part of your evaluation, Does Insurance Cover Orforglipron? covers that separately from the clinical-eligibility question this article focuses on.

Why pediatric approval hasn’t happened (yet)

“Not established” is a specific regulatory phrase — it reflects that the trials supporting orforglipron’s approval didn’t include people under 18, not that the drug was tested in that group and rejected. Pharmaceutical companies sometimes pursue pediatric studies and expanded age indications after an adult approval, but that’s a separate, often multi-year regulatory process. As of orforglipron’s current FDA-approved label, there is no pediatric indication, and this article isn’t aware of one — if that changes, it would show up as an update to the official label on DailyMed, which is the authoritative place to check rather than any secondhand summary, including this one.

For context, orforglipron isn’t unusual in being an adult-focused approval within the GLP-1 class: per MedlinePlus drug information, semaglutide injection and tirzepatide injection are both prescribed under FDA-approved labeling aimed at adult populations for their respective indications. Age requirements and any pediatric-use language differ by specific drug and brand, so check each medication’s own label rather than assuming one drug’s age rules apply to another.

Age is one factor among several

Whether orforglipron is appropriate for a given adult — at 25, 45, or 80 — depends on much more than meeting the 18-and-over threshold. A prescriber weighs full medical history, current medications, kidney and liver function, and any conditions the label flags as relevant (like a personal or family history of certain thyroid conditions) before prescribing. Age is a starting filter for eligibility, not the whole evaluation. For what starting treatment typically looks like once that evaluation is done, see First Week on Orforglipron.

Bottom line

Orforglipron (Foundayo) is approved for adults only — its label states that safety and effectiveness haven’t been established in anyone under 18, so it isn’t an option for teens regardless of weight or health status. For adults 65 and older, trial data included a reasonable number of participants and showed no overall difference in safety or effectiveness versus younger adults, though the oldest age bracket (75+) was a small slice of that data. Either way, meeting the age requirement is just the entry point — the actual decision about whether orforglipron fits your situation belongs to you and your prescriber, based on your full health picture. This article is educational information about the FDA label, not medical advice.